Amcad Biomed (ROCO:4188) Change In Receivables : NT$0.24 Mil (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Amcad Biomed Change In Receivables?

Amcad Biomed's change in receivables for the quarter that ended in Mar. 2024 was NT$6.48 Mil. It means Amcad Biomed's Accounts Receivable declined by NT$6.48 Mil from Dec. 2023 to Mar. 2024 .

Amcad Biomed's change in receivables for the fiscal year that ended in Dec. 2023 was NT$-6.80 Mil. It means Amcad Biomed's Accounts Receivable increased by NT$6.80 Mil from Dec. 2022 to Dec. 2023 .

Amcad Biomed's Accounts Receivable for the quarter that ended in Mar. 2024 was NT$4.77 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Amcad Biomed's Days Sales Outstanding for the three months ended in Mar. 2024 was 53.84.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Amcad Biomed's liquidation value for the three months ended in Mar. 2024 was NT$259.26 Mil.

Amcad Biomed Change In Receivables Historical Data

The historical data trend for Amcad Biomed's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amcad Biomed Change In Receivables Chart

Amcad Biomed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-3.44

2.70

-2.71

1.40

-6.80

Amcad Biomed Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.56	-2.11	0.35	-4.48	6.48

Amcad Biomed Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.24 Mil.

Amcad Biomed (ROCO:4188) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Amcad Biomed's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	4.766	/	8.078	*	91
=	53.84

2. In Ben Graham's calculation of liquidation value, Amcad Biomed's accounts receivable are only considered to be worth 75% of book value:

Amcad Biomed's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	271.477	-	29.109	+	0.75 * 4.766	+	0.5 * 26.642
=	259.26

Amcad Biomed Change In Receivables Related Terms

Thank you for viewing the detailed overview of Amcad Biomed's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Amcad Biomed (ROCO:4188) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Amcad Biomed Corp (ROCO:4188) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 167, Fuxing North Road, 5th Floor, Zhongshan District, Taipei, TWN, 104

Website

https://www.amcad.com.tw

Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, a software solution for thyroid nodules analysis; AmCAD-UV, a software device that is used for quantifying and classifying the ultrasonic color intensity data acquired from FDA-cleared ultrasound systems and displaying the noise-reduced color-coded pulsatile signals; AmCAD- U.S, a software device for viewing and quantifying ultrasound image data of backscattered signals; and AmCAD-UO offers detection for obstructive sleep apnea on awake patients to identify the root cause of sleep apnea. The company's geographical segments include Taiwan, China, and other countries, out of which the majority of the revenue is generated from China.

Amcad Biomed (ROCO:4188) Headlines

No Headlines